National Stroke Foundation

Alphagan (brimonidine)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved September 1996

Specific Treatments:

open-angle glaucoma and ocular hypertension

Therapeutic Areas

General Information

Alphagan has been approved for the treatment of open-angle glaucoma and ocular hypertension.

Mechanism of Action

Alphagan is a selective alpha-2 agonist, which significantly lowers intraocular pressure with minimal effects on cardiovascular and pulmonary parameters. Its unique dual mechanism of action lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.

Additional Information

Glaucoma, an eye disease commonly characterized by excessive intraocular pressure, is a leading cause of blindness in the world.